Switch to:
Also traded in: Brazil, Chile, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:GILD's Cash-to-Debt is ranked higher than
99% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. NAS:GILD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:GILD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.23  Med: 1.44 Max: No Debt
Current: No Debt
Equity-to-Asset 0.34
NAS:GILD's Equity-to-Asset is ranked lower than
82% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:GILD: 0.34 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:GILD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.54 Max: 0.9
Current: 0.34
0.34
0.9
Interest Coverage 18.29
NAS:GILD's Interest Coverage is ranked lower than
82% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:GILD: 18.29 )
Ranked among companies with meaningful Interest Coverage only.
NAS:GILD' s Interest Coverage Range Over the Past 10 Years
Min: 11.11  Med: 34.31 Max: 165.23
Current: 18.29
11.11
165.23
Piotroski F-Score: 5
Altman Z-Score: 3.58
Beneish M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 57.99
NAS:GILD's Operating Margin % is ranked higher than
97% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. NAS:GILD: 57.99 )
Ranked among companies with meaningful Operating Margin % only.
NAS:GILD' s Operating Margin % Range Over the Past 10 Years
Min: 40.39  Med: 50.27 Max: 68
Current: 57.99
40.39
68
Net Margin % 44.41
NAS:GILD's Net Margin % is ranked higher than
96% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:GILD: 44.41 )
Ranked among companies with meaningful Net Margin % only.
NAS:GILD' s Net Margin % Range Over the Past 10 Years
Min: 26.72  Med: 37.34 Max: 55.48
Current: 44.41
26.72
55.48
ROE % 80.30
NAS:GILD's ROE % is ranked higher than
98% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. NAS:GILD: 80.30 )
Ranked among companies with meaningful ROE % only.
NAS:GILD' s ROE % Range Over the Past 10 Years
Min: 29.34  Med: 49.35 Max: 107.62
Current: 80.3
29.34
107.62
ROA % 25.57
NAS:GILD's ROA % is ranked higher than
97% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. NAS:GILD: 25.57 )
Ranked among companies with meaningful ROA % only.
NAS:GILD' s ROA % Range Over the Past 10 Years
Min: 13.37  Med: 28.41 Max: 43.73
Current: 25.57
13.37
43.73
ROC (Joel Greenblatt) % 565.76
NAS:GILD's ROC (Joel Greenblatt) % is ranked higher than
98% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NAS:GILD: 565.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:GILD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 158.48  Med: 176.96 Max: 601.8
Current: 565.76
158.48
601.8
3-Year Revenue Growth Rate 56.90
NAS:GILD's 3-Year Revenue Growth Rate is ranked higher than
90% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NAS:GILD: 56.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:GILD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 7.3  Med: 31.5 Max: 56.9
Current: 56.9
7.3
56.9
3-Year EBITDA Growth Rate 74.30
NAS:GILD's 3-Year EBITDA Growth Rate is ranked higher than
94% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:GILD: 74.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:GILD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -14.5  Med: 38.85 Max: 110
Current: 74.3
-14.5
110
3-Year EPS without NRI Growth Rate 84.40
NAS:GILD's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. NAS:GILD: 84.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:GILD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -15.4  Med: 38.9 Max: 140
Current: 84.4
-15.4
140
GuruFocus has detected 2 Warning Signs with Gilead Sciences Inc $NAS:GILD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:GILD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GILD Guru Trades in Q1 2016

David Dreman 23,210 sh (New)
Leon Cooperman 516,989 sh (New)
George Soros 3,600 sh (New)
Steven Cohen 700 sh (New)
Jeremy Grantham 97,600 sh (+2611.11%)
First Eagle Investment 9,200 sh (+2200.00%)
Paul Tudor Jones 41,349 sh (+148.88%)
Lee Ainslie 5,630 sh (+140.60%)
Dodge & Cox 7,620 sh (+103.20%)
Jerome Dodson 310,000 sh (+55.00%)
Jeff Auxier 2,982 sh (+30.67%)
Ray Dalio 249,821 sh (+14.53%)
Joel Greenblatt 967,642 sh (+10.68%)
Pioneer Investments 3,700,967 sh (+9.08%)
T Rowe Price Equity Income Fund 1,353,600 sh (+8.29%)
David Carlson 570,000 sh (+3.64%)
John Rogers 1,360,492 sh (+3.58%)
Ronald Muhlenkamp 217,990 sh (+0.01%)
Murray Stahl 10,000 sh (unchged)
Ronald Muhlenkamp 3,200 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 327,100 sh (unchged)
Diamond Hill Capital Sold Out
Louis Moore Bacon Sold Out
John Buckingham 63,487 sh (-0.48%)
RS Investment Management 151,102 sh (-2.66%)
Mario Gabelli 40,690 sh (-4.71%)
Ken Fisher 487,030 sh (-13.63%)
NWQ Managers 116,000 sh (-30.50%)
Jim Simons 723,948 sh (-68.79%)
Julian Robertson 38,511 sh (-90.24%)
» More
Q2 2016

GILD Guru Trades in Q2 2016

John Burbank 730,472 sh (New)
Zeke Ashton 21,500 sh (New)
Steven Cohen 659,100 sh (+94057.14%)
Jeremy Grantham 423,100 sh (+333.50%)
First Eagle Investment 15,500 sh (+68.48%)
Ray Dalio 374,672 sh (+49.98%)
Jim Simons 1,079,348 sh (+49.09%)
David Carlson 730,000 sh (+28.07%)
Lee Ainslie 7,020 sh (+24.69%)
John Rogers 1,443,305 sh (+6.09%)
Joel Greenblatt 1,016,142 sh (+5.01%)
T Rowe Price Equity Income Fund 1,375,000 sh (+1.58%)
Murray Stahl 10,050 sh (+0.50%)
John Buckingham 63,649 sh (+0.26%)
Jeff Auxier 2,982 sh (unchged)
Ronald Muhlenkamp 3,200 sh (unchged)
Julian Robertson 38,511 sh (unchged)
Westport Asset Management 95,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 327,100 sh (unchged)
Leon Cooperman Sold Out
George Soros Sold Out
Ronald Muhlenkamp 217,000 sh (-0.45%)
David Dreman 22,546 sh (-2.86%)
Pioneer Investments 3,465,144 sh (-6.37%)
NWQ Managers 108,300 sh (-6.64%)
Ken Fisher 446,493 sh (-8.32%)
Mario Gabelli 35,819 sh (-11.97%)
Jerome Dodson 265,000 sh (-14.52%)
Dodge & Cox 3,750 sh (-50.79%)
Paul Tudor Jones 13,751 sh (-66.74%)
RS Investment Management 29,512 sh (-80.47%)
» More
Q3 2016

GILD Guru Trades in Q3 2016

First Eagle Investment 49,700 sh (+220.65%)
Jeremy Grantham 1,165,716 sh (+175.52%)
Jim Simons 1,947,048 sh (+80.39%)
Jeff Auxier 4,782 sh (+60.36%)
Jerome Dodson 350,000 sh (+32.08%)
Zeke Ashton 25,000 sh (+16.28%)
Murray Stahl 11,550 sh (+14.93%)
Lee Ainslie 7,880 sh (+12.25%)
John Rogers 1,532,528 sh (+6.18%)
T Rowe Price Equity Income Fund 1,425,000 sh (+3.64%)
Eaton Vance Worldwide Health Sciences Fund 635,263 sh (+94.21%)
David Carlson 730,000 sh (unchged)
First Eagle Investment 300 sh (unchged)
Ronald Muhlenkamp 7,500 sh (unchged)
Julian Robertson 38,511 sh (unchged)
John Burbank 5,000,000 sh (unchged)
Dodge & Cox 3,750 sh (unchged)
Ken Fisher 444,529 sh (-0.44%)
John Buckingham 62,994 sh (-1.03%)
Ronald Muhlenkamp 214,495 sh (-1.15%)
David Dreman 21,855 sh (-3.06%)
Pioneer Investments 3,293,651 sh (-4.95%)
Joel Greenblatt 923,534 sh (-9.11%)
Ray Dalio 315,272 sh (-15.85%)
NWQ Managers 81,896 sh (-24.38%)
Mario Gabelli 12,414 sh (-65.34%)
Steven Cohen 141,000 sh (-78.61%)
Paul Tudor Jones 2,800 sh (-79.64%)
John Burbank 3,224 sh (-99.56%)
» More
Q4 2016

GILD Guru Trades in Q4 2016

Tom Gayner 14,000 sh (New)
Paul Tudor Jones 11,401 sh (+307.18%)
Jim Simons 5,274,948 sh (+170.92%)
Jerome Dodson 490,000 sh (+40.00%)
Murray Stahl 13,000 sh (+12.55%)
Joel Greenblatt 1,025,203 sh (+11.01%)
Lee Ainslie 8,520 sh (+8.12%)
John Rogers 1,584,199 sh (+3.37%)
Ken Fisher 455,496 sh (+2.47%)
T Rowe Price Equity Income Fund 1,425,000 sh (unchged)
David Carlson 730,000 sh (unchged)
First Eagle Investment 49,700 sh (unchged)
First Eagle Investment 300 sh (unchged)
Ronald Muhlenkamp 14,800 sh (unchged)
Mario Gabelli 12,414 sh (unchged)
Julian Robertson 38,511 sh (unchged)
John Burbank Sold Out
Steven Cohen Sold Out
Ronald Muhlenkamp 212,995 sh (-0.70%)
David Dreman 20,724 sh (-5.18%)
John Buckingham 59,446 sh (-5.63%)
Dodge & Cox 3,250 sh (-13.33%)
Zeke Ashton 21,000 sh (-16.00%)
Pioneer Investments 2,722,308 sh (-17.35%)
Jeremy Grantham 874,684 sh (-24.97%)
NWQ Managers 61,056 sh (-25.45%)
Ray Dalio 80,272 sh (-74.54%)
Eaton Vance Worldwide Health Sciences Fund 550,067 sh (-13.41%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CELG, NYSE:NVO, NAS:BIIB, OTCPK:SHPGF, NAS:AMGN, OTCPK:CSLLY, NAS:REGN, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, OTCPK:GIKLY, NAS:BMRN, OTCPK:UCBJY, OTCPK:GMXAY, OTCPK:NVZMF, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:UTHR » details
Traded in other countries:GILD34.Brazil, GILD.Chile, GIS.Germany, GILD.Mexico, GILD.Switzerland,
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.

Gilead Sciences Inc was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its operations include offices in Europe, North America, Asia, South America, Africa, Australia, India and the Middle East. It markets products in the HIV, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise of, Truvada, which is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Europe, Australia and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors; ease of patient compliance; patent protection; ease of use; price; insurance and other reimbursement coverage; distribution; and marketing. The Company owns various trademarks and trade names used in its business, including the following: GILEAD, GILEAD SCIENCES, TRUVADA, VIREAD, HEPSERA, AMBISOME, EMTRIVA, VISTIDE, LETAIRIS, VOLIBRIS(tm), RANEXA and CAYSTON. The C

Ratios

vs
industry
vs
history
PE Ratio 7.24
GILD's PE Ratio is ranked higher than
88% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. GILD: 7.24 )
Ranked among companies with meaningful PE Ratio only.
GILD' s PE Ratio Range Over the Past 10 Years
Min: 6.64  Med: 8.78 Max: 15.08
Current: 7.24
6.64
15.08
Forward PE Ratio 7.39
GILD's Forward PE Ratio is ranked higher than
89% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. GILD: 7.39 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 7.24
GILD's PE Ratio without NRI is ranked higher than
89% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. GILD: 7.24 )
Ranked among companies with meaningful PE Ratio without NRI only.
GILD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.64  Med: 8.78 Max: 15.08
Current: 7.24
6.64
15.08
Price-to-Owner-Earnings 6.24
GILD's Price-to-Owner-Earnings is ranked higher than
87% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. GILD: 6.24 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GILD' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.7  Med: 8.12 Max: 15.04
Current: 6.24
5.7
15.04
PB Ratio 4.75
GILD's PB Ratio is ranked lower than
61% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. GILD: 4.75 )
Ranked among companies with meaningful PB Ratio only.
GILD' s PB Ratio Range Over the Past 10 Years
Min: 4.32  Med: 8.43 Max: 11.16
Current: 4.75
4.32
11.16
PS Ratio 3.21
GILD's PS Ratio is ranked higher than
81% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. GILD: 3.21 )
Ranked among companies with meaningful PS Ratio only.
GILD' s PS Ratio Range Over the Past 10 Years
Min: 2.95  Med: 4.69 Max: 7.39
Current: 3.21
2.95
7.39
Price-to-Free-Cash-Flow 7.91
GILD's Price-to-Free-Cash-Flow is ranked higher than
89% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. GILD: 7.91 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GILD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.92  Med: 8.37 Max: 14.98
Current: 7.91
5.92
14.98
Price-to-Operating-Cash-Flow 7.57
GILD's Price-to-Operating-Cash-Flow is ranked higher than
90% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. GILD: 7.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GILD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.67  Med: 8.02 Max: 14.33
Current: 7.57
5.67
14.33
EV-to-EBIT 3.42
GILD's EV-to-EBIT is ranked higher than
79% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. GILD: 3.42 )
Ranked among companies with meaningful EV-to-EBIT only.
GILD' s EV-to-EBIT Range Over the Past 10 Years
Min: 3  Med: 7.4 Max: 12.2
Current: 3.42
3
12.2
EV-to-EBITDA 3.26
GILD's EV-to-EBITDA is ranked higher than
79% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. GILD: 3.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
GILD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.9  Med: 7 Max: 11.4
Current: 3.26
2.9
11.4
PEG Ratio 0.13
GILD's PEG Ratio is ranked higher than
97% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. GILD: 0.13 )
Ranked among companies with meaningful PEG Ratio only.
GILD' s PEG Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.16 Max: 0.75
Current: 0.13
0.11
0.75
Shiller PE Ratio 18.01
GILD's Shiller PE Ratio is ranked higher than
85% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. GILD: 18.01 )
Ranked among companies with meaningful Shiller PE Ratio only.
GILD' s Shiller PE Ratio Range Over the Past 10 Years
Min: 16.43  Med: 32.7 Max: 59.83
Current: 18.01
16.43
59.83
Current Ratio 4.17
GILD's Current Ratio is ranked higher than
50% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. GILD: 4.17 )
Ranked among companies with meaningful Current Ratio only.
GILD' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 4.85 Max: 11.29
Current: 4.17
1.09
11.29
Quick Ratio 4.00
GILD's Quick Ratio is ranked higher than
51% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. GILD: 4.00 )
Ranked among companies with meaningful Quick Ratio only.
GILD' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 4.49 Max: 10.79
Current: 4
0.83
10.79
Days Inventory 157.41
GILD's Days Inventory is ranked lower than
61% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. GILD: 157.41 )
Ranked among companies with meaningful Days Inventory only.
GILD' s Days Inventory Range Over the Past 10 Years
Min: 141.66  Med: 226.7 Max: 284.53
Current: 157.41
141.66
284.53
Days Sales Outstanding 56.08
GILD's Days Sales Outstanding is ranked higher than
56% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. GILD: 56.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
GILD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.22  Med: 69.31 Max: 84.93
Current: 56.08
54.22
84.93
Days Payable 88.92
GILD's Days Payable is ranked higher than
67% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. GILD: 88.92 )
Ranked among companies with meaningful Days Payable only.
GILD' s Days Payable Range Over the Past 10 Years
Min: 88.92  Med: 160.35 Max: 207.21
Current: 88.92
88.92
207.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.63
GILD's Dividend Yield % is ranked higher than
72% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. GILD: 2.63 )
Ranked among companies with meaningful Dividend Yield % only.
GILD' s Dividend Yield % Range Over the Past 10 Years
Min: 0.35  Med: 1.9 Max: 2.79
Current: 2.63
0.35
2.79
Dividend Payout Ratio 0.17
GILD's Dividend Payout Ratio is ranked higher than
91% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. GILD: 0.17 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GILD' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.15 Max: 0.19
Current: 0.17
0.11
0.19
Forward Dividend Yield % 2.97
GILD's Forward Dividend Yield % is ranked higher than
84% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.38 vs. GILD: 2.97 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.63
GILD's 5-Year Yield-on-Cost % is ranked higher than
62% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. GILD: 2.63 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GILD' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.35  Med: 1.9 Max: 2.79
Current: 2.63
0.35
2.79
3-Year Average Share Buyback Ratio 5.10
GILD's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. GILD: 5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GILD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.3  Med: 0.2 Max: 6.1
Current: 5.1
-16.3
6.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 105.97
GILD's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. GILD: 105.97 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GILD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 103.83  Med: 112.31 Max: 112.31
Current: 105.97
103.83
112.31
Price-to-Tangible-Book 9.93
GILD's Price-to-Tangible-Book is ranked lower than
79% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. GILD: 9.93 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GILD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 9.73  Med: 20.41 Max: 46.43
Current: 9.93
9.73
46.43
Price-to-Intrinsic-Value-Projected-FCF 0.63
GILD's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
95% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. GILD: 0.63 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GILD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.61  Med: 1.31 Max: 2.09
Current: 0.63
0.61
2.09
Price-to-Median-PS-Value 0.46
GILD's Price-to-Median-PS-Value is ranked higher than
83% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. GILD: 0.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GILD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.45  Med: 1.05 Max: 1.47
Current: 0.46
0.45
1.47
Price-to-Peter-Lynch-Fair-Value 0.28
GILD's Price-to-Peter-Lynch-Fair-Value is ranked higher than
97% of the 72 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. GILD: 0.28 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GILD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.28  Med: 0.35 Max: 0.7
Current: 0.28
0.28
0.7
Price-to-Graham-Number 1.76
GILD's Price-to-Graham-Number is ranked higher than
62% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. GILD: 1.76 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GILD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.73  Med: 2.79 Max: 5.26
Current: 1.76
1.73
5.26
Earnings Yield (Greenblatt) % 29.56
GILD's Earnings Yield (Greenblatt) % is ranked higher than
95% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. GILD: 29.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GILD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 8.2  Med: 13.6 Max: 33.4
Current: 29.56
8.2
33.4
Forward Rate of Return (Yacktman) % 71.67
GILD's Forward Rate of Return (Yacktman) % is ranked higher than
97% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. GILD: 71.67 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GILD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 22.6  Med: 54 Max: 72.5
Current: 71.67
22.6
72.5

More Statistics

Revenue (TTM) (Mil) $30,390
EPS (TTM) $ 9.94
Beta1.03
Short Percentage of Float0.95%
52-Week Range $65.38 - 103.10
Shares Outstanding (Mil)1,310.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 26,272 25,520 24,233
EPS ($) 9.63 9.44 9.66
EPS without NRI ($) 9.63 9.44 9.66
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-5.61%
Dividends per Share ($) 1.95 1.88 1.88
» More Articles for NAS:GILD

Headlines

Articles On GuruFocus.com
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
10 Undervalued Stocks for the Enterprising Investor Feb 16 2017 
Under the Microscope: Gilead's Recent Dividend Increase Feb 15 2017 
Consider Gilead Sciences Feb 14 2017 
Gilead Sciences, Fossil Reach 3-Year Low Prices Feb 12 2017 
How BioVie, Conatus and PhaseRX Tackle Liver Diseases Feb 08 2017 
10 Low PE Stock Picks for the Enterprising Investor Feb 04 2017 
5 Companies Near 52-Week Lows Feb 03 2017 
John Paulson's Bargain Stock Jan 30 2017 
10 Undervalued Stocks for the Enterprising Investor Jan 26 2017 

More From Other Websites
Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink Feb 24 2017
NASH Is Todd Hagopian's Top Biotech Sub-Sector For 2017 Feb 24 2017
Ten Stocks That Still Look Cheap Feb 24 2017
7 Ultra-Cheap Value Stocks to Buy Now Feb 24 2017
Gilead Sciences Expects a Fall in Its HCV Product Sales in 2017 Feb 24 2017
AbbVie Stronger Bet Than Gilead, Amgen — At Least Until 2020: Leerink Feb 23 2017
Gilead Sciences, Inc. (GILD) EPCLUSA Access To Be Provided In Ontario For Treatment Of Hepatitis C Feb 23 2017
Baby Boomers: Gilead’s New Hep C Target Group Feb 23 2017
This Strategy Could Boost GILD’s HIV Franchise Revenue in 2017 Feb 23 2017
These Regimens Are Expected to See Solid Global Demand in 2017 Feb 23 2017
Big Pharma Quietly Enlists Leading Professors to Justify $1,000-a-Day Drugs Feb 23 2017
Solid Uptake of This Drug Could Drive Gilead’s 2017 Product Sales Feb 23 2017
Cramer: Why Gilead could be a value trap Feb 22 2017
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017
Gilead, Glaxo Pitted In HIV Battle; Both Struggle Vs. Standard Drugs Feb 22 2017
Gilead Sciences Expects to Witness an Earnings Fall in 2017 Feb 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)